As April 2025 unfolds, Asian markets are navigating a complex landscape shaped by escalating trade tensions between the U.S. and China, which have led to increased tariffs and heightened global economic uncertainty. Amidst this backdrop, identifying high-growth tech stocks requires careful consideration of companies that demonstrate resilience through innovation and adaptability in the face of shifting trade policies and market volatility.
Click here to see the full list of 492 stocks from our Asian High Growth Tech and AI Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a company engaged in the development, production, and sale of diagnostic reagents and vaccines, with a market cap of approximately CN¥85.80 billion.
Operations: Beijing Wantai Biological Pharmacy Enterprise focuses on producing diagnostic reagents and vaccines. The company’s revenue streams are primarily driven by these two segments, contributing significantly to its overall financial performance.
Beijing Wantai Biological Pharmacy Enterprise has demonstrated a robust growth trajectory with an anticipated revenue increase of 66.7% per year, outpacing the Chinese market’s average of 12.7%. Despite a challenging year with earnings declining by 91.5%, the company is set for a significant turnaround, projecting an earnings growth of 91.6% annually over the next three years. This rebound is particularly noteworthy in light of a substantial one-off loss of CN¥59M last year, which heavily impacted financial results. The firm’s strategic focus on expanding its biotech segment could catalyze future growth, leveraging advanced R&D capabilities that have historically aligned with industry demands for innovative healthcare solutions.
SHSE:603392 Earnings and Revenue Growth as at Apr 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Maxscend Microelectronics Company Limited focuses on the research, development, production, and sale of radio frequency integrated circuits in China, with a market capitalization of CN¥45.66 billion.
Operations: Maxscend Microelectronics derives its revenue primarily from merchandise sales, totaling approximately CN¥4.47 billion, with additional income from premium services and IP authorization. The company’s business operations are centered on the development and sale of radio frequency integrated circuits in China.
Maxscend Microelectronics, with its recent annual revenue reaching CNY 4.49 billion, demonstrates robust growth in the competitive tech sector of Asia. Despite a significant drop in net income from CNY 1.12 billion to CNY 402 million last year, the company is poised for recovery with its strategic investments in R&D and innovative technologies. Notably, their commitment to research has led to a dynamic product lineup catering to high-profile clients, setting a solid foundation for future growth amidst market fluctuations and evolving industry demands.
SZSE:300782 Earnings and Revenue Growth as at Apr 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: International Games System Co., Ltd. engages in the planning, design, research, development, manufacturing, marketing, servicing, and licensing of arcade, online, and mobile games primarily in Taiwan, the United Kingdom, and China with a market cap of NT$231.92 billion.
Operations: The company generates revenue through its Online Games Division, contributing NT$11.51 billion, and the Business Game Division, which adds NT$7.01 billion.
International Games SystemLtd. has shown notable growth, with its annual revenue increasing by 17.8% and earnings growing by 41% over the past year, outpacing the entertainment industry’s growth of 33.3%. This performance is supported by a significant R&D commitment, which is evident from their latest financials where sales rose to TWD 18.51 billion from TWD 14.18 billion year-over-year, and net income surged to TWD 9.06 billion from TWD 6.43 billion. The company’s strategic focus on innovation not only enhances its product offerings but also solidifies its competitive edge in Asia’s tech landscape.
TPEX:3293 Earnings and Revenue Growth as at Apr 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHSE:603392 SZSE:300782 and TPEX:3293.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
